• Coronavirus cases in the US exceed eight million. Source
• France imposes curfews in nine of its major cities. Source
• The NIH announces the launch of a 2,100-person, phase III trial of three different immunomodulators (Remicade from J & J, Orencia from BMS, and an experimental drug called ceniciviroc from AbbVie), to see if they can control immune overreaction among people hospitalized with moderate to severe COVID-19. Source
• Pfizer CEO, Albert Bourla, announces shift in coronavirus vaccine timeline, postponing it to late November 2020. Source
• Gilead critiques the results from Solidarity, saying that it is “…concerned that the data from this open- label global trial have not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design,” and that “The trial design prioritized broad access, resulting in significant heterogeneity in trial adoption, implementation, controls and patient populations and consequently, it is unclear if any conclusive findings can be drawn from the study results.” Source
